Chiesi Global Rare Diseases has launched the second edition of its Find For Rare research grants programme, aimed at supporting studies into Fabry disease, alpha-mannosidosis and nephropathic cystinosis.

The initiative was unveiled during the 63rd European Renal Association (ERA) Congress in Glasgow, where the company is also presenting research focused on Fabry disease and nephropathic cystinosis.

Find For Rare is an independently assessed, expert-led funding programme designed to support innovative research into lysosomal storage disorders. Chiesi said the initiative aims to advance scientific understanding of the diseases and support improvements in patient care through new research projects and collaboration across the rare disease community.

The programme focuses on three rare inherited conditions: Fabry disease, alpha-mannosidosis and nephropathic cystinosis. All are lysosomal storage disorders, a group of conditions caused by enzyme deficiencies that lead to the build-up of substances within cells and can result in progressive organ damage.

Alongside the grant programme launch, Chiesi is contributing scientific presentations at ERA 2026 examining real-world experience and clinical outcomes in Fabry disease and nephropathic cystinosis.

The company said its Fabry disease research highlights treatment tolerability and immunogenicity, while its cystinosis work explores the role of nephrology-led multidisciplinary care in improving patient outcomes.

Enrico Piccinini, senior vice president Europe and international at Chiesi Global Rare Diseases, said: “Scientific progress in rare diseases is built over time, through continuous dialogue and collaboration.

“At ERA, we are proud to contribute to advancing understanding of lysosomal storage disorders. At the same time, with Find For Rare, we aim to go one step further supporting innovative research that can expand knowledge and help shape the future of care for generations to come.”

Fabry disease is a rare inherited disorder caused by mutations in the GLA gene, resulting in a deficiency of the enzyme alpha-galactosidase A. The condition can affect multiple organs, including the kidneys, heart and nervous system, and may lead to progressive complications if left untreated.

Nephropathic cystinosis is an ultra-rare genetic disease characterised by the accumulation of cystine within cells. The condition primarily affects the kidneys but can also cause damage to other organs over time, often requiring lifelong management and, in many cases, kidney transplantation.

Chiesi said the Find For Rare programme is intended to support research that could improve understanding of these conditions and contribute to future advances in disease management.